Metabolic and weight-management peptides (UK overview)

Weight management is the loudest peptide conversation in the UK consumer space, driven almost entirely by GLP-1 medications since 2022 to 2023. The space splits into two distinct lanes that should not be confused.

Lane one is the licensed-medicine lane. GLP-1 medications including semaglutide and tirzepatide are licensed by the MHRA for weight management in specific patient groups, prescribed by UK doctors via GMC-registered prescribers, and dispensed by GPhC-regulated pharmacies. We maintain a dedicated set of pages on this lane covering NHS access, private clinics, switching, aftercare, perimenopause and PCOS considerations, the high-protein dietary requirement, and the GLP-1 face phenomenon. Newer compounds in this lane (retatrutide is the most-watched 2026 candidate) are not yet UK-licensed for weight management but are in late-stage clinical trials.

Lane two is the research lane. AOD-9604 (a synthetic fragment of human growth hormone) has historical pre-clinical interest in fat metabolism. Cagrilintide is a long-acting amylin analogue under development by Novo Nordisk; the licensed combination with semaglutide is in clinical trials. MOTS-c has metabolic-modulator interest via the mitochondrial pathway. Several UK research peptide retailers stock these compounds under research-use-only framing.

Important boundary: branded comparison of licensed GLP-1 medications is restricted under UK advertising rules. We discuss the class generically (GLP-1 medications, GLP-1 plus amylin combinations, dual and triple agonists) except in editorial contexts where the specific medication is the topic. We do not directly advertise or compare branded prescription products.

Important boundary: research peptides in this category should not be marketed or framed as substitutes for licensed weight-loss medications. They are research compounds. Any clinical decision about weight management should involve a UK prescriber and licensed medication.

The lead-quality difference between the two lanes is meaningful. A UK GLP-1 clinic prescriber takes legal responsibility for the prescription, the dose, the bloods, and the adverse event monitoring. A research peptide retailer takes no clinical responsibility, only product fulfilment. Buyers should sit in the right lane for their situation.